Most Pharmaceutical Companies Receive Poor Grades on HIV/AIDS Drug Development Innovation, According to AIDS Treatment Activist Coalition Report Card; Many Companies Get Low Marks in Five Benchmark Treatment Categories; New Drugs Need to Reflect

September 2009
Ascribe Newswire: Health;9/10/2009, p1
The article reports on the poor grades received by most U.S. pharmaceutical companies on HIV and AIDS drug development innovation. According to AIDS Treatment Activist Coalition Report Card, most companies obtain low marks in five benchmark treatment categories. It indicates that many pharmaceutical companies are not developing innovative, new long-term treatment alternatives that offer improved efficacy, safety and tolerability when taken for decades.


Related Articles

  • CNE/CME QUESTIONS.  // AIDS Alert;May2010, Vol. 25 Issue 5, p59 

    A quiz is presented related to medical care for human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) patients.

  • CNE/CME questions.  // AIDS Alert;Feb2009, Vol. 24 Issue 2, p23 

    A quiz concerning the treatment for HIV and AIDS is presented.

  • Metabonomics Treats Attrition in Early Drug Discovery. Kube, D.M. // Drug Discovery & Development;Mar2003, Vol. 6 Issue 3, p45 

    Discusses the applications of metabonomics in the screening for drug safety and efficacy. Definition of metabonomics; Profiling of metabolites to evaluate the physiological status of an organism as a whole; Link of metabonomics to genomics, transcriptomics and proteomics; Advantages of...

  • Accelerating drug discovery. Kraljevic, Sandra; Stambrook, Peter J.; Pavelic, Kresimir // EMBO Reports;Sep2004, Vol. 5 Issue 9, p837 

    Provides some insights into the drug development process and its implications for the pharmaceutical industry. Investments in drug development in the U.S. and Europe; Issues on drug safety, quality and efficacy; Industrial costs and market trends.

  • Drug Watch.  // Formulary;Dec2005, Vol. 40 Issue 12, p460 

    The article reports on news and developments in pharmaceuticals. A chart is provided on selected dermatologic disorders. Selected literature on calcipotriene/betamethasone, ceftobiprole , dalnavancin and oritavancin is presented. A drug development setback on tazarotene for the treatment of...

  • ...as companies plan combination trial. H.G. // Nature;3/2/1995, Vol. 374 Issue 6517, p4 

    Reports on the start of clinical trials designed by American pharmaceutical companies' Inter Company Collaboration to evaluate the relative effectiveness of different combinations of antiviral drugs against AIDS. Addition of protease inhibitors to the combination trials.

  • In praise of the "devil". Bonaccorso, Silvia; Smith, Richard // BMJ: British Medical Journal (International Edition);5/31/2003, Vol. 326 Issue 7400, p1220 

    Comments on the opinions of physicians and the public toward the pharmaceutical industry, and the view that the industry has been demonized. View that the prejudice against the industry is unfair; Value of pharmaceutical companies in developing countries, where they may provide medical...

  • Beijing Leads in Drug R&D.  // China Chemical Reporter;4/21/2010, Vol. 21 Issue 8, p17 

    The article reports on the development of the first AIDS controlling drug, V9722, by the China Technology Exchange in April 2010.

  • Less Toxic, DDC and DTC Show Promise. Helquist, Michael // Advocate;5/26/87, Issue 473, p23 

    Reports on the tests conducted on a new AIDS drug called dideoxycitidine or DDC. Composition; Action against HIV-infected cells.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics